High prevalence of gastroesophageal reflux disease (GERD) to foster the growth of the ranitidine market

 

Ranitidine Market

Ranitidine, an anti-platelet drug, is the second most popular choice among diabetics to lower blood sugar. The main properties of Ranitidine are its glycoside bound trimethylester, trihalomethanes (THMs), and its suppression of platelet activity. It was first introduced in the United States in 1981 and is now available throughout the world. Ranitidine (also known as Niaspan) is most useful for treating gastric ulcers and conditions such as gastritis, cholecystitis, and duodenal ulcers caused by Helicobacter pylori infection. Ranitidine has a faster onset of action than that of metformin, a commonly prescribed ulcer drug.

The growing prevalence of high prevalence of gastroesophageal reflux disease (GERD) and stomach ulcers is propelling the growth of the ranitidine market. According to the National Center for Biotechnology Information, in the United States, peptic ulcer disease affects approximately 4.6 million people annually, with an estimated 10% of the US population having evidence of a duodenal ulcer at some time. H pylori infection accounts for 90% of duodenal ulcers and 70%-90% of gastric ulcers. The increasing focus of key manufacturers to introduce innovative and novel drugs for the treatment of gastroesophageal reflux disease is also expected to foster the growth of the market. Furthermore, growing research and development activities for developing the novel drug in order to enhance the treatment efficacy is further anticipated to augment the growth of the ranitidine market.

On the other hand, stringent regulatory guidelines of FDA in the manufacturing and commercialization of drug is expected to restrict the growth of the ranitidine market. For instance, in January 2020, the testing lab has led into the Zantac impurity fray and urged the FDA to recall all ranitidine drugs. Emery Pharma announced that its testing shows that the level of the suspected carcinogen NDMA can increase if the drug is exposed to high heat, even after it has been packaged.

North America is projected to gain significant growth over the forecast period and this is attributed to the increasing launch of novel drugs for the treatment of stomach ulcers. For instance, in February 2018, Drug firm Strides Shasun announced the launch of Ranitidine Tablets USP, 150 mg, used to treat peptic ulcers of the stomach and intestines, in the US markets. Strides is already a key player in the US Ranitidine Rx market with a 32 percent market share.

Key Developments:

1.      In November 2019, Strides Pharma Science has relaunched Ranitidine tablets used in ulcer treatment in the US as the level of NDMA (N-nitrosodimethylamine) in its product was found to be within acceptable limits

2.      In June 2019, ANI Pharmaceuticals, Inc. announced the launch of Ranitidine Capsules, 150mg, and 300mg.  The current annual U.S. market for this product is approximately $40 million.




Comments

Popular posts from this blog

Fitness Equipment Market is doing warm-ups to pull growth-rich opportunities from the growing obesity rates accompanied by the sedentary lifestyles

The market for ureteral stents would benefit from the rising prevalence of urological diseases

The North America Vision Care Market Is Driven by the Increasing Prevalence of Eye Diseases in this Region